









Markets
/
Stocks
/
nasdaq-dhr
/

Danaher Corp

DHR

215.380USD

+0.330+0.15%

Close 10/31, 16:00（ET）Quotes delayed by 15 min

152.12BMarket Cap

43.43P/E TTM



Danaher Corp

215.380

+0.330+0.15%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Danaher Corp

Currency: USD Updated: 2025-10-31

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Danaher Corp's Score

Industry at a Glance

Industry Ranking

52 / 210

Overall Ranking

146 / 4618

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 25 analysts

Buy

Current Rating

254.210

Target Price

+18.21%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Danaher Corp Highlights

StrengthsRisks

Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three business segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a range of instruments, consumables, services and software that are primarily used by customers to study genomics and the basic building blocks of life, including deoxyribonucleic acid (DNA)and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 20.13%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 20.13%.

Overvalued

The company’s latest PE is 44.11, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 590.97M shares, decreasing 0.57% quarter-over-quarter.

Held by Al Gore

Star Investor Al Gore holds 4.97M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.06.

Financial Health

Currency: USD Updated: 2025-10-31

The company's current financial score is 7.29, which is lower than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 6.05B, representing a year-over-year increase of 4.40%, while its net profit experienced a year-over-year increase of 11.00%.

Score

Industry at a Glance

Previous score

7.29

Change



Financials

7.29

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.37

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.22

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.31

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.25

Key Metrics

Free cash flow

No Data

Danaher Corp's Company Valuation

Currency: USD Updated: 2025-10-31

The company’s current valuation score is 5.27, which is lower than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is 44.11, which is 19.13% below the recent high of 52.55 and 51.92% above the recent low of 21.21.

Score

Industry at a Glance

Previous score

5.27

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 52/210

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-31

The company’s current earnings forecast score is 8.72, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Danaher Corp is 252.50, with a high of 310.00 and a low of 220.00.

Score

Industry at a Glance

Previous score

8.72

Change

Support & Resistance

No Data

Analyst Rating

Based on 25 analysts

Buy

Current Rating

254.210

Target Price

+18.21%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Danaher Corp

DHR

Boston Scientific Corp

BSX

Edwards Lifesciences Corp

Intuitive Surgical Inc

ISRG

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-31

The company’s current price momentum score is 7.20, which is higher than the Healthcare Equipment & Supplies industry's average of 6.65. Sideways: Currently, the stock price is trading between the resistance level at 232.87 and the support level at 200.01, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.18

Change

0.02

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.433

Neutral

RSI(14)

56.558

Neutral

STOCH(KDJ)(9,3,3)

21.574

Sell

ATR(14)

6.652

High Vlolatility

CCI(14)

0.137

Neutral

Williams %R

60.043

Sell

TRIX(12,20)

0.401

Sell

StochRSI(14)

15.089

Oversold

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

216.470

Sell

MA10

217.535

Sell

MA20

212.255

Buy

MA50

203.513

Buy

MA100

202.088

Buy

MA200

203.051

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-31

The company’s current institutional recognition score is 7.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.43. The latest institutional shareholding proportion is 82.53%, representing a quarter-over-quarter decrease of 11.90%. The largest institutional shareholder is The Vanguard, holding a total of 60.48M shares, representing 8.56% of shares outstanding, with 3.53% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

60.48M

+1.31%

Rales (Steven M)

42.24M

-2.87%

Rales (Mitchell P)

34.93M

-0.58%

BlackRock Institutional Trust Company, N.A.

28.88M

-2.61%

State Street Investment Management (US)

27.30M

-0.60%

Wellington Management Company, LLP

17.08M

-3.53%

Capital International Investors

16.45M

+9.18%

T. Rowe Price Associates, Inc.

Star Investors

15.66M

-15.98%

Geode Capital Management, L.L.C.

13.73M

+0.60%

Fidelity Management & Research Company LLC

12.95M

+3.12%

Risk Assessment

Currency: USD Updated: 2025-10-31

The company’s current risk assessment score is 8.51, which is higher than the Healthcare Equipment & Supplies industry's average of 4.56. The company's beta value is 0.82. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.